Hansa Biopharma AB, „Hansa“ or the „Company“ (Nasdaq Stockholm: HNSA), today announced that management will attend the 43rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.
The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.
In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS) and indirect treatment comparison to the International Guillain-Barré Syndrome Outcome Study (IGOS) demonstrating the potential of imlifidase, the Company’s first-generation IgG cleaving molecule, to address a significant unmet need in GBS. Additionally, the GOOD-IDES-02 (Phase 3 trial in anti-GBM) completed enrolment and positive results from the NICE-01 Phase 1 trial and additional 12-month analysis for HNSA-5487, the Company’s second-generation IgG cleaving molecule, demonstrated rapid and robust IgG reduction and redosing potential.
In Gene Therapy, the Company initiated two trials with gene therapy partners: SRP-9001-104 Phase 1b trial in Duchenne Muscular Dystrophy (DMD) with Sarepta Therapeutics, Inc. (Nasdaq: SRPT) and GNT-018-IDES Phase 2 trial in Crigler-Najjar Syndrome with Genethon. In both trials, imlifidase is being evaluated as a pre-treatment to gene therapy in patients with anti-AAV antibodies.
In Transplantation, randomization of the ConfIdeS (pivotal US Phase 3 trial in kidney transplantation) trial was completed. The Company had four consecutive quarters of strong IDEFIRIX (imlifidase) sales across Europe with Q3 2024 being the highest ever quarterly IDEFIRIX sales performance (69.5 MSEK/$6.4M), underscoring the important role that IDEFIRIX can play in desensitization in kidney transplantation.
Manage Consent
Functional Immer aktiv
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.